Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral DS107 in Moderate to Severe Atopic Dermatitis
NCT02864498Phase 2Completed
- Sponsor
- DS Biopharma
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of DS107E in atopic dermatitis (AD) (3 arms), sponsored by DS Biopharma. Primary endpoint: Proportion of Patients Achieving an Investigators Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points at 8 weeks. Started Jan 2017; status: completed.
02
Drugs
DS107E
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02864498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864498.